Nuvectis Pharma Net Tangible Assets

The latest net tangible assets for NVCT is $14M as of March 2026. That compares with $21M in the prior-year period — down 32.1% year over year. Investors often review this figure alongside Nuvectis Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVCT's net tangible assets moved from $21M to $14M — a 32.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nuvectis Pharma's operating scale or balance-sheet position.

A net tangible assets figure of $14M for NVCT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NVCT's net tangible assets ($14M), review year-over-year change from $21M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.